High Prevalence of Clinical Jaundice Associated with Poor Adherence Among Adults on Boosted Atazanavir Antiretroviral Therapy Regimen at the Infectious Disease Institute HIV/AIDS Clinic in Kampala, Uganda Article Swipe
Angella Kigongo Nabakooza
,
Sharon Kitibwakye Nakamanya
,
Eva Laker
,
Elizabeth Katana
,
Noela Owarwo
,
Isaac Lwanga
,
Barbara Castelnuovo
,
Mohammed Lamorde
,
Freddy Eric Kitutu
·
YOU?
·
· 2022
· Open Access
·
· DOI: https://doi.org/10.21203/rs.3.rs-1405649/v1
YOU?
·
· 2022
· Open Access
·
· DOI: https://doi.org/10.21203/rs.3.rs-1405649/v1
Background Boosted atazanavir (ATV/r)-based Antiretroviral Therapy (ART) regimen is recommended by the World Health Organization (WHO) as second line treatment for HIV/AIDS. ATV/r is known to cause clinical jaundice, which may lead to non-adherence to treatment and the attendant treatment failure and drug resistance. We sought to determine the prevalence of clinical jaundice and explore its effect on adherence to the ART regimen. Methods We conducted a cross-sectional study among 236 adult patients taking ATV/r-based ART regimens attending the Infectious Disease Institute (IDI) HIV/AIDS clinic in Kampala, Uganda from April to May 2019. We assessed the study participants by self-report for existing or previous experience of clinical jaundice after their start on ATV/r-based ART regimen. Adherence to the ATV/r-based ART was determined using the 8-item Morisky scale; score 3 was interpreted as good and poor adherence to ART, respectively. Logistic regression was used to explore the effect of clinical jaundice and other sociodemographic factors on adherence to ART regimen. Results Of the 236 participants, majority were female (66.5%) with a mean age of 39.9 (SD 10.8) years and had been on ART for 10 to 13 years (42.8%). Most (69%) were on TDF/3TC backbone and 24% on AZT/3TC backbone. The period and point prevalence of clinical jaundice was 31.8% (95% confidence interval [CI]: 26.1% – 38.1%) and 21.1% (95% CI: 14.9% – 37.5%) respectively. Up to 8.5% (95% CI: 5.5 – 12.8) had poor adherence ( > 3). At multivariable analysis, clinical jaundice was the only predictor of poor adherence (adjusted odds ratio= 2.9, 95% CI: 1.15 – 7.34, p=0.024). Sex, alcohol use, and stigma and discrimination did not achieve statistical significance. Conclusion Our study indicates a high prevalence of clinical jaundice among patients on ATV/r ART regimen and there is association between experiencing clinical jaundice and poor adherence. For patients whose ART adherence is affected by the presence of clinical jaundice; they should be switched to another second-line ART alternative.
Related Topics
Concepts
Medicine
Regimen
Jaundice
Atazanavir
Internal medicine
Antiretroviral therapy
Logistic regression
Pediatrics
Human immunodeficiency virus (HIV)
Viral load
Immunology
Metadata
- Type
- preprint
- Language
- en
- Landing Page
- https://doi.org/10.21203/rs.3.rs-1405649/v1
- https://www.researchsquare.com/article/rs-1405649/latest.pdf
- OA Status
- green
- References
- 16
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4220909082
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4220909082Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.21203/rs.3.rs-1405649/v1Digital Object Identifier
- Title
-
High Prevalence of Clinical Jaundice Associated with Poor Adherence Among Adults on Boosted Atazanavir Antiretroviral Therapy Regimen at the Infectious Disease Institute HIV/AIDS Clinic in Kampala, UgandaWork title
- Type
-
preprintOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2022Year of publication
- Publication date
-
2022-03-07Full publication date if available
- Authors
-
Angella Kigongo Nabakooza, Sharon Kitibwakye Nakamanya, Eva Laker, Elizabeth Katana, Noela Owarwo, Isaac Lwanga, Barbara Castelnuovo, Mohammed Lamorde, Freddy Eric KitutuList of authors in order
- Landing page
-
https://doi.org/10.21203/rs.3.rs-1405649/v1Publisher landing page
- PDF URL
-
https://www.researchsquare.com/article/rs-1405649/latest.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
greenOpen access status per OpenAlex
- OA URL
-
https://www.researchsquare.com/article/rs-1405649/latest.pdfDirect OA link when available
- Concepts
-
Medicine, Regimen, Jaundice, Atazanavir, Internal medicine, Antiretroviral therapy, Logistic regression, Pediatrics, Human immunodeficiency virus (HIV), Viral load, ImmunologyTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- References (count)
-
16Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4220909082 |
|---|---|
| doi | https://doi.org/10.21203/rs.3.rs-1405649/v1 |
| ids.doi | https://doi.org/10.21203/rs.3.rs-1405649/v1 |
| ids.openalex | https://openalex.org/W4220909082 |
| fwci | |
| type | preprint |
| title | High Prevalence of Clinical Jaundice Associated with Poor Adherence Among Adults on Boosted Atazanavir Antiretroviral Therapy Regimen at the Infectious Disease Institute HIV/AIDS Clinic in Kampala, Uganda |
| biblio.issue | |
| biblio.volume | |
| biblio.last_page | |
| biblio.first_page | |
| topics[0].id | https://openalex.org/T10082 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9987999796867371 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2725 |
| topics[0].subfield.display_name | Infectious Diseases |
| topics[0].display_name | HIV/AIDS Research and Interventions |
| topics[1].id | https://openalex.org/T10526 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9980000257492065 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2725 |
| topics[1].subfield.display_name | Infectious Diseases |
| topics[1].display_name | HIV/AIDS drug development and treatment |
| topics[2].id | https://openalex.org/T10112 |
| topics[2].field.id | https://openalex.org/fields/24 |
| topics[2].field.display_name | Immunology and Microbiology |
| topics[2].score | 0.9901000261306763 |
| topics[2].domain.id | https://openalex.org/domains/1 |
| topics[2].domain.display_name | Life Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2406 |
| topics[2].subfield.display_name | Virology |
| topics[2].display_name | HIV Research and Treatment |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C71924100 |
| concepts[0].level | 0 |
| concepts[0].score | 0.8507332801818848 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[0].display_name | Medicine |
| concepts[1].id | https://openalex.org/C2781413609 |
| concepts[1].level | 2 |
| concepts[1].score | 0.7988411784172058 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q7308373 |
| concepts[1].display_name | Regimen |
| concepts[2].id | https://openalex.org/C2778456037 |
| concepts[2].level | 2 |
| concepts[2].score | 0.7514121532440186 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q133244 |
| concepts[2].display_name | Jaundice |
| concepts[3].id | https://openalex.org/C2778414717 |
| concepts[3].level | 5 |
| concepts[3].score | 0.5487261414527893 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q423467 |
| concepts[3].display_name | Atazanavir |
| concepts[4].id | https://openalex.org/C126322002 |
| concepts[4].level | 1 |
| concepts[4].score | 0.5258622169494629 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[4].display_name | Internal medicine |
| concepts[5].id | https://openalex.org/C2993143319 |
| concepts[5].level | 4 |
| concepts[5].score | 0.4635303318500519 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q583050 |
| concepts[5].display_name | Antiretroviral therapy |
| concepts[6].id | https://openalex.org/C151956035 |
| concepts[6].level | 2 |
| concepts[6].score | 0.41142722964286804 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q1132755 |
| concepts[6].display_name | Logistic regression |
| concepts[7].id | https://openalex.org/C187212893 |
| concepts[7].level | 1 |
| concepts[7].score | 0.377375066280365 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q123028 |
| concepts[7].display_name | Pediatrics |
| concepts[8].id | https://openalex.org/C3013748606 |
| concepts[8].level | 2 |
| concepts[8].score | 0.3676382601261139 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q15787 |
| concepts[8].display_name | Human immunodeficiency virus (HIV) |
| concepts[9].id | https://openalex.org/C142462285 |
| concepts[9].level | 3 |
| concepts[9].score | 0.33553197979927063 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q2528140 |
| concepts[9].display_name | Viral load |
| concepts[10].id | https://openalex.org/C203014093 |
| concepts[10].level | 1 |
| concepts[10].score | 0.2414616048336029 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q101929 |
| concepts[10].display_name | Immunology |
| keywords[0].id | https://openalex.org/keywords/medicine |
| keywords[0].score | 0.8507332801818848 |
| keywords[0].display_name | Medicine |
| keywords[1].id | https://openalex.org/keywords/regimen |
| keywords[1].score | 0.7988411784172058 |
| keywords[1].display_name | Regimen |
| keywords[2].id | https://openalex.org/keywords/jaundice |
| keywords[2].score | 0.7514121532440186 |
| keywords[2].display_name | Jaundice |
| keywords[3].id | https://openalex.org/keywords/atazanavir |
| keywords[3].score | 0.5487261414527893 |
| keywords[3].display_name | Atazanavir |
| keywords[4].id | https://openalex.org/keywords/internal-medicine |
| keywords[4].score | 0.5258622169494629 |
| keywords[4].display_name | Internal medicine |
| keywords[5].id | https://openalex.org/keywords/antiretroviral-therapy |
| keywords[5].score | 0.4635303318500519 |
| keywords[5].display_name | Antiretroviral therapy |
| keywords[6].id | https://openalex.org/keywords/logistic-regression |
| keywords[6].score | 0.41142722964286804 |
| keywords[6].display_name | Logistic regression |
| keywords[7].id | https://openalex.org/keywords/pediatrics |
| keywords[7].score | 0.377375066280365 |
| keywords[7].display_name | Pediatrics |
| keywords[8].id | https://openalex.org/keywords/human-immunodeficiency-virus |
| keywords[8].score | 0.3676382601261139 |
| keywords[8].display_name | Human immunodeficiency virus (HIV) |
| keywords[9].id | https://openalex.org/keywords/viral-load |
| keywords[9].score | 0.33553197979927063 |
| keywords[9].display_name | Viral load |
| keywords[10].id | https://openalex.org/keywords/immunology |
| keywords[10].score | 0.2414616048336029 |
| keywords[10].display_name | Immunology |
| language | en |
| locations[0].id | doi:10.21203/rs.3.rs-1405649/v1 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S4306402450 |
| locations[0].source.issn | |
| locations[0].source.type | repository |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | |
| locations[0].source.is_core | False |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Research Square (Research Square) |
| locations[0].source.host_organization | https://openalex.org/I4210096694 |
| locations[0].source.host_organization_name | Research Square (United States) |
| locations[0].source.host_organization_lineage | https://openalex.org/I4210096694 |
| locations[0].license | cc-by |
| locations[0].pdf_url | https://www.researchsquare.com/article/rs-1405649/latest.pdf |
| locations[0].version | acceptedVersion |
| locations[0].raw_type | posted-content |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | False |
| locations[0].raw_source_name | |
| locations[0].landing_page_url | https://doi.org/10.21203/rs.3.rs-1405649/v1 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5062705021 |
| authorships[0].author.orcid | |
| authorships[0].author.display_name | Angella Kigongo Nabakooza |
| authorships[0].countries | UG |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I72227227 |
| authorships[0].affiliations[0].raw_affiliation_string | Makerere University College of Health Sciences |
| authorships[0].affiliations[1].institution_ids | https://openalex.org/I72227227 |
| authorships[0].affiliations[1].raw_affiliation_string | Noela Owarwo Makerere University College of Health Sciences |
| authorships[0].affiliations[2].institution_ids | https://openalex.org/I72227227 |
| authorships[0].affiliations[2].raw_affiliation_string | Pharmacy Department, Makerere University School of Health Sciences Sharon Kitibwakye Nakamanya Pharmacy Department, Makerere University School of Health Sciences |
| authorships[0].affiliations[3].institution_ids | https://openalex.org/I72227227 |
| authorships[0].affiliations[3].raw_affiliation_string | Sustainable Pharmaceutical Systems (SPS) unit, Makerere University School of Health Sciences |
| authorships[0].affiliations[4].institution_ids | https://openalex.org/I72227227 |
| authorships[0].affiliations[4].raw_affiliation_string | Eva Laker Makerere University College of Health Sciences |
| authorships[0].institutions[0].id | https://openalex.org/I72227227 |
| authorships[0].institutions[0].ror | https://ror.org/03dmz0111 |
| authorships[0].institutions[0].type | education |
| authorships[0].institutions[0].lineage | https://openalex.org/I72227227 |
| authorships[0].institutions[0].country_code | UG |
| authorships[0].institutions[0].display_name | Makerere University |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Angella Kigongo Nabakooza |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Eva Laker Makerere University College of Health Sciences, Makerere University College of Health Sciences, Noela Owarwo Makerere University College of Health Sciences, Pharmacy Department, Makerere University School of Health Sciences Sharon Kitibwakye Nakamanya Pharmacy Department, Makerere University School of Health Sciences, Sustainable Pharmaceutical Systems (SPS) unit, Makerere University School of Health Sciences |
| authorships[1].author.id | https://openalex.org/A5082375346 |
| authorships[1].author.orcid | |
| authorships[1].author.display_name | Sharon Kitibwakye Nakamanya |
| authorships[1].countries | UG |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I72227227 |
| authorships[1].affiliations[0].raw_affiliation_string | Pharmacy Department, Makerere University School of Health Sciences |
| authorships[1].institutions[0].id | https://openalex.org/I72227227 |
| authorships[1].institutions[0].ror | https://ror.org/03dmz0111 |
| authorships[1].institutions[0].type | education |
| authorships[1].institutions[0].lineage | https://openalex.org/I72227227 |
| authorships[1].institutions[0].country_code | UG |
| authorships[1].institutions[0].display_name | Makerere University |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Sharon Kitibwakye Nakamanya |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Pharmacy Department, Makerere University School of Health Sciences |
| authorships[2].author.id | https://openalex.org/A5042780925 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-7937-1538 |
| authorships[2].author.display_name | Eva Laker |
| authorships[2].countries | UG |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I72227227 |
| authorships[2].affiliations[0].raw_affiliation_string | Makerere University College of Health Sciences |
| authorships[2].institutions[0].id | https://openalex.org/I72227227 |
| authorships[2].institutions[0].ror | https://ror.org/03dmz0111 |
| authorships[2].institutions[0].type | education |
| authorships[2].institutions[0].lineage | https://openalex.org/I72227227 |
| authorships[2].institutions[0].country_code | UG |
| authorships[2].institutions[0].display_name | Makerere University |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Eva Laker |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Makerere University College of Health Sciences |
| authorships[3].author.id | https://openalex.org/A5062583512 |
| authorships[3].author.orcid | https://orcid.org/0000-0001-5415-5778 |
| authorships[3].author.display_name | Elizabeth Katana |
| authorships[3].countries | UG |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I72227227 |
| authorships[3].affiliations[0].raw_affiliation_string | Eva Laker Makerere University College of Health Sciences |
| authorships[3].affiliations[1].institution_ids | https://openalex.org/I72227227 |
| authorships[3].affiliations[1].raw_affiliation_string | Noela Owarwo Makerere University College of Health Sciences |
| authorships[3].affiliations[2].institution_ids | https://openalex.org/I72227227 |
| authorships[3].affiliations[2].raw_affiliation_string | Pharmacy Department, Makerere University School of Health Sciences Sharon Kitibwakye Nakamanya Pharmacy Department, Makerere University School of Health Sciences |
| authorships[3].affiliations[3].institution_ids | https://openalex.org/I72227227 |
| authorships[3].affiliations[3].raw_affiliation_string | Sustainable Pharmaceutical Systems (SPS) unit, Makerere University School of Health Sciences |
| authorships[3].affiliations[4].institution_ids | https://openalex.org/I72227227 |
| authorships[3].affiliations[4].raw_affiliation_string | Makerere University College of Health Sciences |
| authorships[3].institutions[0].id | https://openalex.org/I72227227 |
| authorships[3].institutions[0].ror | https://ror.org/03dmz0111 |
| authorships[3].institutions[0].type | education |
| authorships[3].institutions[0].lineage | https://openalex.org/I72227227 |
| authorships[3].institutions[0].country_code | UG |
| authorships[3].institutions[0].display_name | Makerere University |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Elizabeth Katana |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Eva Laker Makerere University College of Health Sciences, Makerere University College of Health Sciences, Noela Owarwo Makerere University College of Health Sciences, Pharmacy Department, Makerere University School of Health Sciences Sharon Kitibwakye Nakamanya Pharmacy Department, Makerere University School of Health Sciences, Sustainable Pharmaceutical Systems (SPS) unit, Makerere University School of Health Sciences |
| authorships[4].author.id | https://openalex.org/A5079514075 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-3455-2116 |
| authorships[4].author.display_name | Noela Owarwo |
| authorships[4].countries | UG |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I72227227 |
| authorships[4].affiliations[0].raw_affiliation_string | Makerere University College of Health Sciences |
| authorships[4].institutions[0].id | https://openalex.org/I72227227 |
| authorships[4].institutions[0].ror | https://ror.org/03dmz0111 |
| authorships[4].institutions[0].type | education |
| authorships[4].institutions[0].lineage | https://openalex.org/I72227227 |
| authorships[4].institutions[0].country_code | UG |
| authorships[4].institutions[0].display_name | Makerere University |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Noela Owarwo |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Makerere University College of Health Sciences |
| authorships[5].author.id | https://openalex.org/A5112493088 |
| authorships[5].author.orcid | https://orcid.org/0000-0003-2961-9686 |
| authorships[5].author.display_name | Isaac Lwanga |
| authorships[5].countries | UG |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I72227227 |
| authorships[5].affiliations[0].raw_affiliation_string | Eva Laker Makerere University College of Health Sciences |
| authorships[5].affiliations[1].institution_ids | https://openalex.org/I72227227 |
| authorships[5].affiliations[1].raw_affiliation_string | Noela Owarwo Makerere University College of Health Sciences |
| authorships[5].affiliations[2].institution_ids | https://openalex.org/I72227227 |
| authorships[5].affiliations[2].raw_affiliation_string | Sustainable Pharmaceutical Systems (SPS) unit, Makerere University School of Health Sciences |
| authorships[5].affiliations[3].institution_ids | https://openalex.org/I72227227 |
| authorships[5].affiliations[3].raw_affiliation_string | Pharmacy Department, Makerere University School of Health Sciences Sharon Kitibwakye Nakamanya Pharmacy Department, Makerere University School of Health Sciences |
| authorships[5].affiliations[4].institution_ids | https://openalex.org/I72227227 |
| authorships[5].affiliations[4].raw_affiliation_string | Makerere University College of Health Sciences |
| authorships[5].institutions[0].id | https://openalex.org/I72227227 |
| authorships[5].institutions[0].ror | https://ror.org/03dmz0111 |
| authorships[5].institutions[0].type | education |
| authorships[5].institutions[0].lineage | https://openalex.org/I72227227 |
| authorships[5].institutions[0].country_code | UG |
| authorships[5].institutions[0].display_name | Makerere University |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Isaac Lwanga |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Eva Laker Makerere University College of Health Sciences, Makerere University College of Health Sciences, Noela Owarwo Makerere University College of Health Sciences, Pharmacy Department, Makerere University School of Health Sciences Sharon Kitibwakye Nakamanya Pharmacy Department, Makerere University School of Health Sciences, Sustainable Pharmaceutical Systems (SPS) unit, Makerere University School of Health Sciences |
| authorships[6].author.id | https://openalex.org/A5067597194 |
| authorships[6].author.orcid | https://orcid.org/0000-0001-7756-5032 |
| authorships[6].author.display_name | Barbara Castelnuovo |
| authorships[6].countries | UG |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I72227227 |
| authorships[6].affiliations[0].raw_affiliation_string | Pharmacy Department, Makerere University School of Health Sciences Sharon Kitibwakye Nakamanya Pharmacy Department, Makerere University School of Health Sciences |
| authorships[6].affiliations[1].institution_ids | https://openalex.org/I72227227 |
| authorships[6].affiliations[1].raw_affiliation_string | Makerere University College of Health Sciences |
| authorships[6].affiliations[2].institution_ids | https://openalex.org/I72227227 |
| authorships[6].affiliations[2].raw_affiliation_string | Eva Laker Makerere University College of Health Sciences |
| authorships[6].affiliations[3].institution_ids | https://openalex.org/I72227227 |
| authorships[6].affiliations[3].raw_affiliation_string | Noela Owarwo Makerere University College of Health Sciences |
| authorships[6].affiliations[4].institution_ids | https://openalex.org/I72227227 |
| authorships[6].affiliations[4].raw_affiliation_string | Sustainable Pharmaceutical Systems (SPS) unit, Makerere University School of Health Sciences |
| authorships[6].institutions[0].id | https://openalex.org/I72227227 |
| authorships[6].institutions[0].ror | https://ror.org/03dmz0111 |
| authorships[6].institutions[0].type | education |
| authorships[6].institutions[0].lineage | https://openalex.org/I72227227 |
| authorships[6].institutions[0].country_code | UG |
| authorships[6].institutions[0].display_name | Makerere University |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Barbara Castelnuovo |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Eva Laker Makerere University College of Health Sciences, Makerere University College of Health Sciences, Noela Owarwo Makerere University College of Health Sciences, Pharmacy Department, Makerere University School of Health Sciences Sharon Kitibwakye Nakamanya Pharmacy Department, Makerere University School of Health Sciences, Sustainable Pharmaceutical Systems (SPS) unit, Makerere University School of Health Sciences |
| authorships[7].author.id | https://openalex.org/A5068703662 |
| authorships[7].author.orcid | https://orcid.org/0000-0003-2218-6822 |
| authorships[7].author.display_name | Mohammed Lamorde |
| authorships[7].countries | UG |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I72227227 |
| authorships[7].affiliations[0].raw_affiliation_string | Eva Laker Makerere University College of Health Sciences |
| authorships[7].affiliations[1].institution_ids | https://openalex.org/I72227227 |
| authorships[7].affiliations[1].raw_affiliation_string | Makerere University College of Health Sciences |
| authorships[7].affiliations[2].institution_ids | https://openalex.org/I72227227 |
| authorships[7].affiliations[2].raw_affiliation_string | Pharmacy Department, Makerere University School of Health Sciences Sharon Kitibwakye Nakamanya Pharmacy Department, Makerere University School of Health Sciences |
| authorships[7].affiliations[3].institution_ids | https://openalex.org/I72227227 |
| authorships[7].affiliations[3].raw_affiliation_string | Noela Owarwo Makerere University College of Health Sciences |
| authorships[7].affiliations[4].institution_ids | https://openalex.org/I72227227 |
| authorships[7].affiliations[4].raw_affiliation_string | Sustainable Pharmaceutical Systems (SPS) unit, Makerere University School of Health Sciences |
| authorships[7].institutions[0].id | https://openalex.org/I72227227 |
| authorships[7].institutions[0].ror | https://ror.org/03dmz0111 |
| authorships[7].institutions[0].type | education |
| authorships[7].institutions[0].lineage | https://openalex.org/I72227227 |
| authorships[7].institutions[0].country_code | UG |
| authorships[7].institutions[0].display_name | Makerere University |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Mohammed Lamorde |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Eva Laker Makerere University College of Health Sciences, Makerere University College of Health Sciences, Noela Owarwo Makerere University College of Health Sciences, Pharmacy Department, Makerere University School of Health Sciences Sharon Kitibwakye Nakamanya Pharmacy Department, Makerere University School of Health Sciences, Sustainable Pharmaceutical Systems (SPS) unit, Makerere University School of Health Sciences |
| authorships[8].author.id | https://openalex.org/A5070817307 |
| authorships[8].author.orcid | https://orcid.org/0000-0003-2277-9572 |
| authorships[8].author.display_name | Freddy Eric Kitutu |
| authorships[8].countries | UG |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I72227227 |
| authorships[8].affiliations[0].raw_affiliation_string | Noela Owarwo Makerere University College of Health Sciences |
| authorships[8].affiliations[1].institution_ids | https://openalex.org/I72227227 |
| authorships[8].affiliations[1].raw_affiliation_string | Makerere University College of Health Sciences |
| authorships[8].affiliations[2].institution_ids | https://openalex.org/I72227227 |
| authorships[8].affiliations[2].raw_affiliation_string | Pharmacy Department, Makerere University School of Health Sciences Sharon Kitibwakye Nakamanya Pharmacy Department, Makerere University School of Health Sciences |
| authorships[8].affiliations[3].institution_ids | https://openalex.org/I72227227 |
| authorships[8].affiliations[3].raw_affiliation_string | Sustainable Pharmaceutical Systems (SPS) unit, Makerere University School of Health Sciences |
| authorships[8].affiliations[4].institution_ids | https://openalex.org/I72227227 |
| authorships[8].affiliations[4].raw_affiliation_string | Eva Laker Makerere University College of Health Sciences |
| authorships[8].institutions[0].id | https://openalex.org/I72227227 |
| authorships[8].institutions[0].ror | https://ror.org/03dmz0111 |
| authorships[8].institutions[0].type | education |
| authorships[8].institutions[0].lineage | https://openalex.org/I72227227 |
| authorships[8].institutions[0].country_code | UG |
| authorships[8].institutions[0].display_name | Makerere University |
| authorships[8].author_position | last |
| authorships[8].raw_author_name | Freddy Eric Kitutu |
| authorships[8].is_corresponding | True |
| authorships[8].raw_affiliation_strings | Eva Laker Makerere University College of Health Sciences, Makerere University College of Health Sciences, Noela Owarwo Makerere University College of Health Sciences, Pharmacy Department, Makerere University School of Health Sciences Sharon Kitibwakye Nakamanya Pharmacy Department, Makerere University School of Health Sciences, Sustainable Pharmaceutical Systems (SPS) unit, Makerere University School of Health Sciences |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://www.researchsquare.com/article/rs-1405649/latest.pdf |
| open_access.oa_status | green |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | High Prevalence of Clinical Jaundice Associated with Poor Adherence Among Adults on Boosted Atazanavir Antiretroviral Therapy Regimen at the Infectious Disease Institute HIV/AIDS Clinic in Kampala, Uganda |
| has_fulltext | True |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10082 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9987999796867371 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2725 |
| primary_topic.subfield.display_name | Infectious Diseases |
| primary_topic.display_name | HIV/AIDS Research and Interventions |
| related_works | https://openalex.org/W2124214271, https://openalex.org/W2037975995, https://openalex.org/W1500178628, https://openalex.org/W3023094828, https://openalex.org/W2003238700, https://openalex.org/W4235900029, https://openalex.org/W1988019371, https://openalex.org/W2012101483, https://openalex.org/W2168369403, https://openalex.org/W4291127547 |
| cited_by_count | 0 |
| locations_count | 1 |
| best_oa_location.id | doi:10.21203/rs.3.rs-1405649/v1 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S4306402450 |
| best_oa_location.source.issn | |
| best_oa_location.source.type | repository |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | |
| best_oa_location.source.is_core | False |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Research Square (Research Square) |
| best_oa_location.source.host_organization | https://openalex.org/I4210096694 |
| best_oa_location.source.host_organization_name | Research Square (United States) |
| best_oa_location.source.host_organization_lineage | https://openalex.org/I4210096694 |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | https://www.researchsquare.com/article/rs-1405649/latest.pdf |
| best_oa_location.version | acceptedVersion |
| best_oa_location.raw_type | posted-content |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | False |
| best_oa_location.raw_source_name | |
| best_oa_location.landing_page_url | https://doi.org/10.21203/rs.3.rs-1405649/v1 |
| primary_location.id | doi:10.21203/rs.3.rs-1405649/v1 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S4306402450 |
| primary_location.source.issn | |
| primary_location.source.type | repository |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | |
| primary_location.source.is_core | False |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Research Square (Research Square) |
| primary_location.source.host_organization | https://openalex.org/I4210096694 |
| primary_location.source.host_organization_name | Research Square (United States) |
| primary_location.source.host_organization_lineage | https://openalex.org/I4210096694 |
| primary_location.license | cc-by |
| primary_location.pdf_url | https://www.researchsquare.com/article/rs-1405649/latest.pdf |
| primary_location.version | acceptedVersion |
| primary_location.raw_type | posted-content |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | False |
| primary_location.raw_source_name | |
| primary_location.landing_page_url | https://doi.org/10.21203/rs.3.rs-1405649/v1 |
| publication_date | 2022-03-07 |
| publication_year | 2022 |
| referenced_works | https://openalex.org/W2035304784, https://openalex.org/W3018157587, https://openalex.org/W1981655325, https://openalex.org/W2559683026, https://openalex.org/W3135230955, https://openalex.org/W3023485439, https://openalex.org/W2032329090, https://openalex.org/W2174327850, https://openalex.org/W1984238213, https://openalex.org/W6608275964, https://openalex.org/W2914569405, https://openalex.org/W2765555351, https://openalex.org/W2078862756, https://openalex.org/W2161620966, https://openalex.org/W202974098, https://openalex.org/W2665204160 |
| referenced_works_count | 16 |
| abstract_inverted_index.( | 239 |
| abstract_inverted_index.3 | 132 |
| abstract_inverted_index.a | 67, 173, 280 |
| abstract_inverted_index.10 | 187 |
| abstract_inverted_index.13 | 189 |
| abstract_inverted_index.At | 242 |
| abstract_inverted_index.Of | 164 |
| abstract_inverted_index.Up | 228 |
| abstract_inverted_index.We | 45, 65, 94 |
| abstract_inverted_index.as | 17, 135 |
| abstract_inverted_index.be | 318 |
| abstract_inverted_index.by | 11, 99, 310 |
| abstract_inverted_index.in | 86 |
| abstract_inverted_index.is | 9, 24, 294, 308 |
| abstract_inverted_index.of | 51, 106, 151, 176, 208, 251, 283, 313 |
| abstract_inverted_index.on | 58, 112, 158, 184, 195, 200, 288 |
| abstract_inverted_index.or | 103 |
| abstract_inverted_index.to | 26, 33, 35, 47, 60, 91, 117, 140, 147, 160, 188, 229, 320 |
| abstract_inverted_index.(SD | 178 |
| abstract_inverted_index.236 | 71, 166 |
| abstract_inverted_index.24% | 199 |
| abstract_inverted_index.3). | 241 |
| abstract_inverted_index.5.5 | 233 |
| abstract_inverted_index.95% | 258 |
| abstract_inverted_index.ART | 62, 76, 114, 120, 161, 185, 290, 306, 323 |
| abstract_inverted_index.CI: | 223, 232, 259 |
| abstract_inverted_index.For | 303 |
| abstract_inverted_index.May | 92 |
| abstract_inverted_index.Our | 277 |
| abstract_inverted_index.The | 203 |
| abstract_inverted_index.age | 175 |
| abstract_inverted_index.and | 37, 42, 54, 130, 137, 154, 181, 198, 205, 220, 267, 269, 292, 300 |
| abstract_inverted_index.did | 271 |
| abstract_inverted_index.for | 21, 101, 186 |
| abstract_inverted_index.had | 182, 236 |
| abstract_inverted_index.its | 56 |
| abstract_inverted_index.may | 31 |
| abstract_inverted_index.not | 272 |
| abstract_inverted_index.the | 12, 38, 49, 61, 79, 96, 118, 124, 149, 165, 248, 311 |
| abstract_inverted_index.was | 121, 133, 145, 211, 247 |
| abstract_inverted_index.– | 218, 225, 234, 261 |
| abstract_inverted_index.> | 131, 240 |
| abstract_inverted_index.(95% | 213, 222, 231 |
| abstract_inverted_index.1.15 | 260 |
| abstract_inverted_index.2.9, | 257 |
| abstract_inverted_index.39.9 | 177 |
| abstract_inverted_index.8.5% | 230 |
| abstract_inverted_index.ART, | 141 |
| abstract_inverted_index.Most | 192 |
| abstract_inverted_index.Sex, | 264 |
| abstract_inverted_index.been | 183 |
| abstract_inverted_index.drug | 43 |
| abstract_inverted_index.from | 89 |
| abstract_inverted_index.good | 136 |
| abstract_inverted_index.high | 281 |
| abstract_inverted_index.lead | 32 |
| abstract_inverted_index.line | 19 |
| abstract_inverted_index.mean | 174 |
| abstract_inverted_index.odds | 255 |
| abstract_inverted_index.only | 249 |
| abstract_inverted_index.poor | 138, 237, 252, 301 |
| abstract_inverted_index.they | 316 |
| abstract_inverted_index.use, | 266 |
| abstract_inverted_index.used | 146 |
| abstract_inverted_index.were | 169, 194 |
| abstract_inverted_index.with | 172 |
| abstract_inverted_index.<3 | 129 |
| abstract_inverted_index.(69%) | 193 |
| abstract_inverted_index.(ART) | 7 |
| abstract_inverted_index.(IDI) | 83 |
| abstract_inverted_index.(WHO) | 16 |
| abstract_inverted_index.10.8) | 179 |
| abstract_inverted_index.12.8) | 235 |
| abstract_inverted_index.14.9% | 224 |
| abstract_inverted_index.2019. | 93 |
| abstract_inverted_index.21.1% | 221 |
| abstract_inverted_index.26.1% | 217 |
| abstract_inverted_index.31.8% | 212 |
| abstract_inverted_index.7.34, | 262 |
| abstract_inverted_index.ATV/r | 23, 289 |
| abstract_inverted_index.April | 90 |
| abstract_inverted_index.World | 13 |
| abstract_inverted_index.[CI]: | 216 |
| abstract_inverted_index.adult | 72 |
| abstract_inverted_index.after | 109 |
| abstract_inverted_index.among | 70, 286 |
| abstract_inverted_index.cause | 27 |
| abstract_inverted_index.known | 25 |
| abstract_inverted_index.other | 155 |
| abstract_inverted_index.point | 206 |
| abstract_inverted_index.score | 128 |
| abstract_inverted_index.start | 111 |
| abstract_inverted_index.study | 69, 97, 278 |
| abstract_inverted_index.their | 110 |
| abstract_inverted_index.there | 293 |
| abstract_inverted_index.using | 123 |
| abstract_inverted_index.which | 30 |
| abstract_inverted_index.whose | 305 |
| abstract_inverted_index.years | 180, 190 |
| abstract_inverted_index.37.5%) | 226 |
| abstract_inverted_index.38.1%) | 219 |
| abstract_inverted_index.8-item | 125 |
| abstract_inverted_index.Health | 14 |
| abstract_inverted_index.Uganda | 88 |
| abstract_inverted_index.clinic | 85 |
| abstract_inverted_index.effect | 57, 150 |
| abstract_inverted_index.female | 170 |
| abstract_inverted_index.period | 204 |
| abstract_inverted_index.ratio= | 256 |
| abstract_inverted_index.scale; | 127 |
| abstract_inverted_index.second | 18 |
| abstract_inverted_index.should | 317 |
| abstract_inverted_index.sought | 46 |
| abstract_inverted_index.stigma | 268 |
| abstract_inverted_index.taking | 74 |
| abstract_inverted_index.(66.5%) | 171 |
| abstract_inverted_index.AZT/3TC | 201 |
| abstract_inverted_index.Boosted | 2 |
| abstract_inverted_index.Disease | 81 |
| abstract_inverted_index.Methods | 64 |
| abstract_inverted_index.Morisky | 126 |
| abstract_inverted_index.Results | 163 |
| abstract_inverted_index.TDF/3TC | 196 |
| abstract_inverted_index.Therapy | 6 |
| abstract_inverted_index.achieve | 273 |
| abstract_inverted_index.alcohol | 265 |
| abstract_inverted_index.another | 321 |
| abstract_inverted_index.between | 296 |
| abstract_inverted_index.explore | 55, 148 |
| abstract_inverted_index.factors | 157 |
| abstract_inverted_index.failure | 41 |
| abstract_inverted_index.regimen | 8, 291 |
| abstract_inverted_index.(42.8%). | 191 |
| abstract_inverted_index.Abstract | 0 |
| abstract_inverted_index.HIV/AIDS | 84 |
| abstract_inverted_index.Kampala, | 87 |
| abstract_inverted_index.Logistic | 143 |
| abstract_inverted_index.affected | 309 |
| abstract_inverted_index.assessed | 95 |
| abstract_inverted_index.backbone | 197 |
| abstract_inverted_index.clinical | 28, 52, 107, 152, 209, 245, 284, 298, 314 |
| abstract_inverted_index.existing | 102 |
| abstract_inverted_index.interval | 215 |
| abstract_inverted_index.jaundice | 53, 108, 153, 210, 246, 285, 299 |
| abstract_inverted_index.majority | 168 |
| abstract_inverted_index.patients | 73, 287, 304 |
| abstract_inverted_index.presence | 312 |
| abstract_inverted_index.previous | 104 |
| abstract_inverted_index.regimen. | 63, 115, 162 |
| abstract_inverted_index.regimens | 77 |
| abstract_inverted_index.switched | 319 |
| abstract_inverted_index.(adjusted | 254 |
| abstract_inverted_index.Adherence | 116 |
| abstract_inverted_index.HIV/AIDS. | 22 |
| abstract_inverted_index.Institute | 82 |
| abstract_inverted_index.adherence | 59, 139, 159, 238, 253, 307 |
| abstract_inverted_index.analysis, | 244 |
| abstract_inverted_index.attendant | 39 |
| abstract_inverted_index.attending | 78 |
| abstract_inverted_index.backbone. | 202 |
| abstract_inverted_index.conducted | 66 |
| abstract_inverted_index.determine | 48 |
| abstract_inverted_index.indicates | 279 |
| abstract_inverted_index.jaundice, | 29 |
| abstract_inverted_index.jaundice; | 315 |
| abstract_inverted_index.p=0.024). | 263 |
| abstract_inverted_index.predictor | 250 |
| abstract_inverted_index.treatment | 20, 36, 40 |
| abstract_inverted_index.Background | 1 |
| abstract_inverted_index.Conclusion | 276 |
| abstract_inverted_index.Infectious | 80 |
| abstract_inverted_index.adherence. | 302 |
| abstract_inverted_index.atazanavir | 3 |
| abstract_inverted_index.confidence | 214 |
| abstract_inverted_index.determined | 122 |
| abstract_inverted_index.experience | 105 |
| abstract_inverted_index.prevalence | 50, 207, 282 |
| abstract_inverted_index.regression | 144 |
| abstract_inverted_index.ATV/r-based | 75, 113, 119 |
| abstract_inverted_index.association | 295 |
| abstract_inverted_index.interpreted | 134 |
| abstract_inverted_index.recommended | 10 |
| abstract_inverted_index.resistance. | 44 |
| abstract_inverted_index.second-line | 322 |
| abstract_inverted_index.self-report | 100 |
| abstract_inverted_index.statistical | 274 |
| abstract_inverted_index.Organization | 15 |
| abstract_inverted_index.alternative. | 324 |
| abstract_inverted_index.experiencing | 297 |
| abstract_inverted_index.participants | 98 |
| abstract_inverted_index.(ATV/r)-based | 4 |
| abstract_inverted_index.multivariable | 243 |
| abstract_inverted_index.non-adherence | 34 |
| abstract_inverted_index.participants, | 167 |
| abstract_inverted_index.respectively. | 142, 227 |
| abstract_inverted_index.significance. | 275 |
| abstract_inverted_index.Antiretroviral | 5 |
| abstract_inverted_index.discrimination | 270 |
| abstract_inverted_index.cross-sectional | 68 |
| abstract_inverted_index.sociodemographic | 156 |
| cited_by_percentile_year | |
| corresponding_author_ids | https://openalex.org/A5070817307 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 9 |
| corresponding_institution_ids | https://openalex.org/I72227227 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/1 |
| sustainable_development_goals[0].score | 0.5600000023841858 |
| sustainable_development_goals[0].display_name | No poverty |
| citation_normalized_percentile.value | 0.03507665 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |